These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31023444)

  • 21. Blood pressure targets in patients with chronic kidney disease: MDRD and AASK now confirming SPRINT.
    Sarafidis P; Loutradis C; Ortiz A; Ruilope LM
    Clin Kidney J; 2020 Jun; 13(3):287-290. PubMed ID: 32699614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.
    Bakris GL; Williams M; Dworkin L; Elliott WJ; Epstein M; Toto R; Tuttle K; Douglas J; Hsueh W; Sowers J
    Am J Kidney Dis; 2000 Sep; 36(3):646-61. PubMed ID: 10977801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypertension in chronic kidney disease after the Systolic Blood Pressure Intervention Trial: targets, treatment and current uncertainties.
    Kovesdy CP
    Nephrol Dial Transplant; 2017 Apr; 32(suppl_2):ii219-ii223. PubMed ID: 28201651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood pressure control in patients with chronic kidney disease.
    Lee JY; Han SH
    Korean J Intern Med; 2021 Jul; 36(4):780-794. PubMed ID: 34153181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Specific Blood Pressure Targets for Patients With Diabetic Nephropathy?
    Grassi G; Mancia G; Nilsson PM
    Diabetes Care; 2016 Aug; 39 Suppl 2():S228-33. PubMed ID: 27440837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systolic Blood Pressure Response in SPRINT (Systolic Blood Pressure Intervention Trial) and ACCORD (Action to Control Cardiovascular Risk in Diabetes): A Possible Explanation for Discordant Trial Results.
    Huang C; Dhruva SS; Coppi AC; Warner F; Li SX; Lin H; Nasir K; Krumholz HM
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29133522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypertension in 2016: Blood pressure goals, variability and SGLT2 blockade in CKD.
    Cohen DL; Townsend RR
    Nat Rev Nephrol; 2017 Feb; 13(2):75-76. PubMed ID: 28029152
    [No Abstract]   [Full Text] [Related]  

  • 28. Blood Pressure Variability Predicts Adverse Events and Cardiovascular Outcomes in Chronic Kidney Disease: A Post-Hoc Analysis of the SPRINT Trial.
    Mezue K; Goyal A; Pressman GS; Horrow JC; Rangaswami J
    Am J Hypertens; 2017 Dec; 31(1):48-52. PubMed ID: 28985328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CKD awareness and blood pressure control in the primary care hypertensive population.
    Ravera M; Noberasco G; Weiss U; Re M; Gallina AM; Filippi A; Cannavò R; Ravera G; Cricelli C; Deferrari G
    Am J Kidney Dis; 2011 Jan; 57(1):71-7. PubMed ID: 21087817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What is the ideal blood pressure goal for patients with diabetes mellitus and nephropathy?
    Lipman ML; Schiffrin EL
    Curr Cardiol Rep; 2012 Dec; 14(6):651-9. PubMed ID: 22903734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Kidney in Hypertension.
    Sternlicht H; Bakris GL
    Med Clin North Am; 2017 Jan; 101(1):207-217. PubMed ID: 27884230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implications of Blood Pressure Measurement Technique for Implementation of Systolic Blood Pressure Intervention Trial (SPRINT).
    Agarwal R
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28159816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treating hypertension in diabetic nephropathy.
    Tomlinson JW; Owen KR; Close CF
    Diabetes Care; 2003 Jun; 26(6):1802-5. PubMed ID: 12766113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [What is the goal blood pressure in non-diabetic chronic kidney disease?].
    Krummel T; Keller N; Prinz É; Hannedouche T
    Nephrol Ther; 2018 Nov; 14(6):446-453. PubMed ID: 29503160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hypertension with chronic kidney disease: anti-hypertensive therapy recommended for the management of hypertension with CKD in JSN-CKD GL 2013 and JSH2014].
    Tamura K; Yutoh J; Matsushita K; Sakai M; Oshikawa J
    Nihon Rinsho; 2015 Nov; 73(11):1876-84. PubMed ID: 26619662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of the SPRINT Trial on Hypertension Management.
    Ghazi L; Oparil S
    Annu Rev Med; 2018 Jan; 69():81-95. PubMed ID: 29414255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What Is Wrong with the Blood Pressure Target Recommendation of KDIGO 2021 for Hypertension in Chronic Kidney Disease?
    Jamale T; Kulkarni M; Keskar V
    Nephron; 2023; 147(10):616-620. PubMed ID: 37231907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey).
    Bress AP; Kramer H; Khatib R; Beddhu S; Cheung AK; Hess R; Bansal VK; Cao G; Yee J; Moran AE; Durazo-Arvizu R; Muntner P; Cooper RS
    Circulation; 2017 Apr; 135(17):1617-1628. PubMed ID: 28193605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of SPRINT on the future treatment of hypertension: a mini review.
    Chrysant SG
    Drugs Today (Barc); 2016 Mar; 52(3):193-8. PubMed ID: 27186593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Kidney and hypertension--evidence based medicine].
    Nakao N; Senou H; Kasuga H; Toriyama T; Kawahara H
    Nihon Naika Gakkai Zasshi; 2004 Aug; 93(8):1639-45. PubMed ID: 15384696
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.